Ocular side-effects associated with imatinib mesylate (Gleevec®)

Frederick W. Fraunfelder, Jonathan Solomon, Brian Druker, Bita Esmaeli, Jennifer Kuyl

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

This retrospective case series describes ocular side-effects associated with imatinib mesylate (Gleevec®) and the clinical characteristics of these adverse reactions. A chart review of 104 patients on imatinib mesylate therapy from Oregon Health & Science University's Cancer Center were studied with regard to ocular side-effects. In addition, spontaneous reports from the Food and Drug Administration, the World Health Organization, and the National Registry of Drug-Induced Ocular Side-Effects databases were reviewed, including a Medline literature search. Seventy-three (70%) of the patients at OHSU developed periorbital edema and 19 patients (18%) developed epiphora after receiving imatinib mesylate. Average dose was 407.5 +/-60mg. Periorbital edema occurred an average of 68+/-48 days after initiation of therapy. WHO classification of side-effects is as follows: certain: periorbital edema; probable: epiphora; possible: extraocular muscle palsy, ptosis, blepharoconjunctivitis; unlikely: glaucoma, papilledema, retinal hemorrhage, photosensitivity, abnormal vision, and increased intraocular pressure. Periorbital edema and epiphora are the two most common ocular side-effects related to imatinib mesylate therapy. Clinical characteristics of imatinib mesylate induced periorbital edema are described. Management of ocular side-effects is conservative except in very rare cases of visually significant periorbital edema.

Original languageEnglish (US)
Pages (from-to)371-375
Number of pages5
JournalJournal of Ocular Pharmacology and Therapeutics
Volume19
Issue number4
DOIs
StatePublished - Aug 2003

Fingerprint

Edema
Lacrimal Apparatus Diseases
Oculomotor Muscles
Retinal Hemorrhage
Papilledema
United States Food and Drug Administration
Intraocular Pressure
Paralysis
Glaucoma
Registries
Imatinib Mesylate
Therapeutics
Databases
Health
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Ophthalmology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Ocular side-effects associated with imatinib mesylate (Gleevec®). / Fraunfelder, Frederick W.; Solomon, Jonathan; Druker, Brian; Esmaeli, Bita; Kuyl, Jennifer.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 19, No. 4, 08.2003, p. 371-375.

Research output: Contribution to journalArticle

Fraunfelder, Frederick W. ; Solomon, Jonathan ; Druker, Brian ; Esmaeli, Bita ; Kuyl, Jennifer. / Ocular side-effects associated with imatinib mesylate (Gleevec®). In: Journal of Ocular Pharmacology and Therapeutics. 2003 ; Vol. 19, No. 4. pp. 371-375.
@article{c0ff91fd4b044a1f80f271449e270a84,
title = "Ocular side-effects associated with imatinib mesylate (Gleevec{\circledR})",
abstract = "This retrospective case series describes ocular side-effects associated with imatinib mesylate (Gleevec{\circledR}) and the clinical characteristics of these adverse reactions. A chart review of 104 patients on imatinib mesylate therapy from Oregon Health & Science University's Cancer Center were studied with regard to ocular side-effects. In addition, spontaneous reports from the Food and Drug Administration, the World Health Organization, and the National Registry of Drug-Induced Ocular Side-Effects databases were reviewed, including a Medline literature search. Seventy-three (70{\%}) of the patients at OHSU developed periorbital edema and 19 patients (18{\%}) developed epiphora after receiving imatinib mesylate. Average dose was 407.5 +/-60mg. Periorbital edema occurred an average of 68+/-48 days after initiation of therapy. WHO classification of side-effects is as follows: certain: periorbital edema; probable: epiphora; possible: extraocular muscle palsy, ptosis, blepharoconjunctivitis; unlikely: glaucoma, papilledema, retinal hemorrhage, photosensitivity, abnormal vision, and increased intraocular pressure. Periorbital edema and epiphora are the two most common ocular side-effects related to imatinib mesylate therapy. Clinical characteristics of imatinib mesylate induced periorbital edema are described. Management of ocular side-effects is conservative except in very rare cases of visually significant periorbital edema.",
author = "Fraunfelder, {Frederick W.} and Jonathan Solomon and Brian Druker and Bita Esmaeli and Jennifer Kuyl",
year = "2003",
month = "8",
doi = "10.1089/108076803322279426",
language = "English (US)",
volume = "19",
pages = "371--375",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Ocular side-effects associated with imatinib mesylate (Gleevec®)

AU - Fraunfelder, Frederick W.

AU - Solomon, Jonathan

AU - Druker, Brian

AU - Esmaeli, Bita

AU - Kuyl, Jennifer

PY - 2003/8

Y1 - 2003/8

N2 - This retrospective case series describes ocular side-effects associated with imatinib mesylate (Gleevec®) and the clinical characteristics of these adverse reactions. A chart review of 104 patients on imatinib mesylate therapy from Oregon Health & Science University's Cancer Center were studied with regard to ocular side-effects. In addition, spontaneous reports from the Food and Drug Administration, the World Health Organization, and the National Registry of Drug-Induced Ocular Side-Effects databases were reviewed, including a Medline literature search. Seventy-three (70%) of the patients at OHSU developed periorbital edema and 19 patients (18%) developed epiphora after receiving imatinib mesylate. Average dose was 407.5 +/-60mg. Periorbital edema occurred an average of 68+/-48 days after initiation of therapy. WHO classification of side-effects is as follows: certain: periorbital edema; probable: epiphora; possible: extraocular muscle palsy, ptosis, blepharoconjunctivitis; unlikely: glaucoma, papilledema, retinal hemorrhage, photosensitivity, abnormal vision, and increased intraocular pressure. Periorbital edema and epiphora are the two most common ocular side-effects related to imatinib mesylate therapy. Clinical characteristics of imatinib mesylate induced periorbital edema are described. Management of ocular side-effects is conservative except in very rare cases of visually significant periorbital edema.

AB - This retrospective case series describes ocular side-effects associated with imatinib mesylate (Gleevec®) and the clinical characteristics of these adverse reactions. A chart review of 104 patients on imatinib mesylate therapy from Oregon Health & Science University's Cancer Center were studied with regard to ocular side-effects. In addition, spontaneous reports from the Food and Drug Administration, the World Health Organization, and the National Registry of Drug-Induced Ocular Side-Effects databases were reviewed, including a Medline literature search. Seventy-three (70%) of the patients at OHSU developed periorbital edema and 19 patients (18%) developed epiphora after receiving imatinib mesylate. Average dose was 407.5 +/-60mg. Periorbital edema occurred an average of 68+/-48 days after initiation of therapy. WHO classification of side-effects is as follows: certain: periorbital edema; probable: epiphora; possible: extraocular muscle palsy, ptosis, blepharoconjunctivitis; unlikely: glaucoma, papilledema, retinal hemorrhage, photosensitivity, abnormal vision, and increased intraocular pressure. Periorbital edema and epiphora are the two most common ocular side-effects related to imatinib mesylate therapy. Clinical characteristics of imatinib mesylate induced periorbital edema are described. Management of ocular side-effects is conservative except in very rare cases of visually significant periorbital edema.

UR - http://www.scopus.com/inward/record.url?scp=0041971163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041971163&partnerID=8YFLogxK

U2 - 10.1089/108076803322279426

DO - 10.1089/108076803322279426

M3 - Article

C2 - 12964961

AN - SCOPUS:0041971163

VL - 19

SP - 371

EP - 375

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 4

ER -